Physician profile
Naomi E Ringer
NPI 1225510134
$3,349.85
in general payments reported to CMS, 2019-2025
21 companies · $1,363 in 2025
The $1,363 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $374 · 2022: $564 · 2023: $117 · 2024: $932 · 2025: $1,363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,412.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $580.23 | 2021-2024 | Arexvy |
| Phathom Pharmaceuticals, INC. | $430.68 | 2024-2025 | Voquezna |
| Abbvie INC. | $428.06 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $259.34 | 2025 | Entyvio, Eohilia |
| Genzyme Corporation | $214.64 | 2022-2025 | |
| Ardelyx, INC. | $166.93 | 2024 | Ibsrela |
| Madrigal Pharmaceuticals | $166.19 | 2025 | Rezdiffra |
| Qol Medical, LLC | $142.32 | 2024-2025 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $134.12 | 2024-2025 | Tremfya, Stelara, Simponi |
| United Therapeutics Corporation | $125.00 | 2021 | |
| Harmony Biosciences LLC | $124.50 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.72 | 2021 | |
| Paratek Pharmaceuticals, INC. | $110.05 | 2022 | |
| Lilly USA, LLC | $94.53 | 2024-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $62.76 | 2024-2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $46.79 | 2024-2025 | Dupixent |
| Celltrion USA INC. | $43.54 | 2025 | Vegzelma |
| Celgene Corporation | $26.21 | 2024 | Zeposia |
| Novo Nordisk INC | $25.92 | 2025 | Wegovy |
| Enterra Medical, INC. | $22.24 | 2025 | |
| Aimmune Therapeutics, INC. | $22.08 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naomi Ringer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.